➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Colorcon
Merck
Moodys
Dow

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TELMISARTAN AND AMLODIPINE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Telmisartan And Amlodipine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00240474 ↗ A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study) Completed Boehringer Ingelheim Phase 4 2002-12-01 The primary objective of this study was test non-inferiority of telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in reducing ambulatory systolic blood pressure (SBP) in the last 6 hours of the 24-hour dosing interval (determined by ambulatory blood pressure monitoring: ABPM) in elderly patients with predominantly systolic hypertension.
NCT00242814 ↗ Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities Completed Boehringer Ingelheim Phase 4 2005-10-01 The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome. Moreover, this study will compare serum level of inflammatory markers of the metabolic syndrome after 6 weeks of treatment. An ancillary study performed in one center will assess adipocyte differentiation (PPAR gamma stimulation) in 30 subjects (15 per arm).
NCT00281580 ↗ Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension Completed Boehringer Ingelheim Phase 3 2006-04-01 To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
NCT00509470 ↗ Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine Completed Tokyo University Phase 4 2007-07-01 The purpose of this study is to compare depressor effect and safety between combination therapy with telmisartan plus low-dose hydrochlorothiazide and amlodipine in hypertensive patients.
NCT00538486 ↗ A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients Completed Third Military Medical University Phase 4 2008-02-01 The epidemic of obesity is associated with a considerable rise in the incidence of the metabolic syndrome, type 2 diabetes mellitus, and hypertension. Insulin resistance plays an important role in the pathogenesis of obesity related hypertension. These patients are at high risk to suffer from cardiovascular events. However, current guidelines for treatment of hypertension do not provide specific recommendation for the pharmacotherapy of obese hypertensive patients due to lack of prospective randomized intervention studies in non-diabetic obese hypertensive patients. Aside from their antihypertensive effects, angiotensin II receptor blockers (ARB) were shown to improve insulin sensitivity. Furthermore, metformin is commonly used to treat the obese type 2 diabetes mellitus. Metformin can also lower body weight and increase insulin sensitivity. In a prospective, double-blind, double-dummy, randomized, parallel-group study, we will evaluate the effects of ARB (telmisartan and candesartan) or amlodipine combination with metformin on weight gain, visceral fat, and metabolic parameters in obese hypertensive patients without diabetes mellitus compared with obese hypertensives on ARB or amlodipine treatment alone. This study will help to develop future comprehensive treatment strategies and guidelines for obesity related hypertension.
NCT00550953 ↗ Filtered Trial for Telmisartan 40mg Non-responder Completed Boehringer Ingelheim Phase 3 2007-10-01 The primary purpose of this study is to: Demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to telmisartan 40 mg alone in patients with essential hypertension and inadequately controlled with telmisartan 40 mg monotherapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Telmisartan And Amlodipine

Condition Name

Condition Name for Telmisartan And Amlodipine
Intervention Trials
Hypertension 54
Healthy 15
Essential Hypertension 7
Hyperlipidemia 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Telmisartan And Amlodipine
Intervention Trials
Hypertension 47
Hyperlipidemias 9
Hyperlipoproteinemias 3
Dyslipidemias 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Telmisartan And Amlodipine

Trials by Country

Trials by Country for Telmisartan And Amlodipine
Location Trials
Korea, Republic of 61
United States 55
Japan 12
Canada 9
China 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Telmisartan And Amlodipine
Location Trials
Texas 3
Oklahoma 3
Georgia 3
Florida 3
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Telmisartan And Amlodipine

Clinical Trial Phase

Clinical Trial Phase for Telmisartan And Amlodipine
Clinical Trial Phase Trials
Phase 4 16
Phase 3 29
Phase 2 2
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Telmisartan And Amlodipine
Clinical Trial Phase Trials
Completed 66
Not yet recruiting 9
Recruiting 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Telmisartan And Amlodipine

Sponsor Name

Sponsor Name for Telmisartan And Amlodipine
Sponsor Trials
Boehringer Ingelheim 36
Chong Kun Dang Pharmaceutical 17
Yuhan Corporation 7
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Telmisartan And Amlodipine
Sponsor Trials
Industry 74
Other 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Mallinckrodt
Dow
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.